Immunological Features and Hypotheses: Do SARS-CoV and MERS-CoV-Reported Individuals have Immunity against SARS-CoV-2 Infection

COVID-19 spreads abnormally compared to its counterparts in the same family beta-coronaviruses. Today, we count more than 130 million affected humans affected by the COVID-19. Therefore, the study of means of prevention and treatment is an urgent need. Interestingly, the novel virus (SARS-CoV-2) has some similarities with SARS-CoV and MERS-CoV. It is known that heterologous immunity is well recognized within species of the same family. The use of previously recognized effective antibodies for SARS and MERS virus may prevent the COVID-19 pandemic. The objective of this study is to compare between SARS-CoV, MERS-CoV, and SARS-CoV-2 genomic and proteomic identity/similarity and their cross-immunity as well as their immunological features in the context of COVID-19 diseases prevention and treatment methods.

Automated summary

COVID-19 has spread abnormally compared to other beta-coronaviruses, affecting over 130 million humans. The study aims to compare the genomic and proteomic characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2, and their potential cross-immunity for prevention and treatment of COVID-19.